Catalent to Discuss Biologic and Small Molecule Drug Development, and Continuous Manufacturing at Upcoming INTERPHEX Convention
SOMERSET, N.J. (PRWEB) April 10, 2018 -- Catalent Pharma Solutions (Booth 1245), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that several of its formulation and manufacturing experts are to present and participate in the educational agenda at the INTERPHEX Conference and Exhibition, to be held the Javits Center, New York City, on April 17 - 19, 2018.
On Tuesday, April 17 at 11:30 a.m., Ronald Vladyka, Director, Formulation Research & Product Development, will take to the INTERPHEX Innovation Stage as part of the Pharmaceutical Technology Keynote Series, and will participate in a roundtable entitled, “Continuous Manufacturing: Best Practices for Implementation.”
Later that day, at 3:30 p.m. Cornell Stamoran, Ph.D., Vice President of Corporate Strategy, will join the Small Molecule Outsourcing Panel, hosted on the PBOA CMO/CDMO stage.
On Wednesday, April 18 at 1:15 p.m., Aileen Ruff, Vice President, Strategy and Marketing, Biologics and Specialty Drug Delivery, will also present on the PBOA CMO/CDMO stage and will discuss “Driving efficiencies in biologic product development by partnering with a single services provider throughout all phases of the supply chain.”
Again, on April 18 on the PBO CMO/CDMO stage, Catalent’s Vice President of Business Development and Marketing, Biologics and Specialty Drug Delivery, Cory Lewis, will participate in a Biologics Outsourcing Panel at 2:15 p.m. At the same time, Alexander Haig, Director of Engineering, Catalent Biologics, will participate in the panel discussion “Central Utilities for GMP Manufacturing: A Practical Dialog on Cost and Reliability,” on the Technical Conference Stage 1, Booth 1076.
As part of the exhibition, Catalent will also showcase its seamless biologics development, formulation and manufacturing capabilities, with its network of North American facilities, including the 900,000-square foot facility in Bloomington, Indiana, which was added through the acquisition of Cook Pharmica in 2017. Additionally, Catalent will be highlighting its broad range of innovative delivery technologies and solutions designed to accelerate development and overcome challenges such pill burden, poor oral bioavailability, and the safe delivery of potent molecules.
For more information on the 2018 INTERPHEX Convention, visit http://www.interphex.com and to arrange a meeting with attending Catalent executives at the event, contact Richard Kerns at NEPR- richard(at)nepr.eu.
About Catalent
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 11,000 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2017 generated over $2 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com
More products. Better treatments. Reliably supplied.™
Chris Halling, Catalent Pharma Solutions, http://www.catalent.com, +44 +44 7580 041073, [email protected]
Share this article